Breakthrough in Chronic Spontaneous Urticaria Treatment: EU Approves First Oral Targeted Therapy

For the nearly 4 million adults in Europe living with chronic spontaneous urticaria (CSU), relief has often been elusive. Despite standard treatments like H1-antihistamines, more than half of patients continue to endure debilitating symptoms—itching, swelling, and unpredictable flares that disrupt sleep, productivity, and emotional well-being. But a new era in CSU management has arrived with the European Commission’s approval of Rhapsido® (remibrutinib), the first oral targeted therapy for this condition.

What Is Chronic Spontaneous Urticaria (CSU)?

CSU is a severe and unpredictable skin disorder characterized by recurrent hives (wheals), deep tissue swelling (angioedema), and intense itching that persists for six weeks or longer without an identifiable trigger. Unlike allergic reactions, CSU arises from internal immune system dysfunction, making it notoriously tricky to treat. For many patients, conventional antihistamines provide little to no relief, leaving them trapped in a cycle of discomfort and frustration.

How Rhapsido® Works: A Game-Changer in CSU Treatment

Rhapsido® is a highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor. BTK plays a critical role in the immune pathway that drives CSU symptoms. By blocking this enzyme, Rhapsido® interrupts the signaling cascade responsible for hives and swelling, offering a targeted approach to symptom control. Unlike injectable biologics or corticosteroids, Rhapsido® is taken as a pill twice daily, with no demand for laboratory monitoring—a significant convenience for patients.

Key Benefits of Rhapsido®

• Rapid Relief: Clinical trials (REMIX 1 & 2) demonstrated significant improvements in symptoms as early as the first week of treatment, with sustained benefits over time.
• Favorable Safety Profile: The studies reported no liver safety concerns, a critical advantage over some existing therapies.
• Guideline-Recommended: Rhapsido® is included in the 2026 International Urticaria Guideline, which recommends it for all patients who remain symptomatic after antihistamine treatment.

Expert Perspectives on the Approval

“CSU is more than just a skin condition—it’s a serious disease that profoundly impacts quality of life,” says Prof. Dr. Med. Martin Metz, Deputy Director of the Institute of Allergology at Charité Universitätsmedizin Berlin. “The approval of Rhapsido® marks a major step forward, offering fast relief by targeting a key immune pathway. This could help a broad range of patients regain control of their disease.”

The European Commission’s decision follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in February 2026, underscoring the therapy’s clinical significance.

Who Is Eligible for Rhapsido®?

Rhapsido® is approved for adults with CSU who have not responded adequately to H1-antihistamine treatment. This includes patients experiencing persistent symptoms despite taking standard doses of antihistamines or those who require frequent dose escalations. The therapy offers a new option for those who have exhausted conventional treatments but still face daily challenges from their condition.

What’s Next for CSU Patients?

With Rhapsido® now available, patients and healthcare providers have a powerful new tool to combat CSU. Novartis, the manufacturer, has emphasized the therapy’s potential to transform the treatment landscape, particularly for those who have struggled with limited options. As more patients gain access to Rhapsido®, real-world data will further clarify its long-term benefits and role in CSU management.

Key Takeaways

• Rhapsido® (remibrutinib) is the first oral targeted therapy approved for chronic spontaneous urticaria (CSU) in Europe.
• It works by inhibiting Bruton’s tyrosine kinase (BTK), a key enzyme in the immune pathway driving CSU symptoms.
• Clinical trials showed rapid symptom improvement (as early as Week 1) and a favorable safety profile with no liver concerns.
• Approved for adults with inadequate response to H1-antihistamines, Rhapsido® is included in the 2026 International Urticaria Guideline.
• Taken as a twice-daily pill, it offers convenience without the need for lab monitoring.

Frequently Asked Questions

How does Rhapsido® differ from antihistamines?

Antihistamines block histamine, a chemical released during allergic reactions, but they don’t address the underlying immune dysfunction in CSU. Rhapsido® targets BTK, a different part of the immune pathway, making it effective for patients who don’t respond to antihistamines alone.

Are there any side effects?

In clinical trials, Rhapsido® demonstrated a favorable safety profile. The most common side effects were mild and included headaches and upper respiratory tract infections. Importantly, no liver safety concerns were reported, which is a notable advantage over some other CSU treatments.

When will Rhapsido® be available?

The European Commission’s approval paves the way for Rhapsido® to be made available to patients in the coming months. Availability may vary by country, so patients should consult their healthcare providers for specific timelines.

Is Rhapsido® a cure for CSU?

Rhapsido® is not a cure, but it offers significant symptom control for many patients. It aims to reduce the frequency and severity of hives and swelling, improving quality of life. Long-term management may still be necessary, depending on the individual’s response.

The Future of CSU Treatment

The approval of Rhapsido® represents a landmark moment in CSU care, offering hope to millions of patients who have long struggled with limited treatment options. As research continues and more patients begin using the therapy, its full impact on the CSU landscape will become clearer. For now, it stands as a testament to the power of targeted, patient-centered innovation in medicine.